Outcomes of prolonged and low-dose ciclosporin in an Asian population

J Dermatolog Treat. 2021 Jun;32(4):432-437. doi: 10.1080/09546634.2019.1662881. Epub 2019 Sep 10.

Abstract

Background: Ciclosporin is used in dermatology for a variety of conditions. Existing guidelines commonly recommend a starting dose of 3-5 mg/kg/day.

Objectives: We sought to assess response in our cohort of patients in whom lower doses of ciclosporin were used, and compare the efficacy and side effect profile with existing literature.

Methods: We retrospectively studied the use of ciclosporin (cyclosporine A) in our dermatological center. Ciclosporin dose trajectories and changes in disease severity were analyzed.

Results: 92 patients were studied (64 with eczema, 17 with psoriasis). Mean initiation ciclosporin dose was relatively low at 1.53 mg/kg/day, with an increase to a mean of 2.61 mg/kg/day at 6 months. The median duration of treatment was 180 days (range 3-2160 days, IQR 383). The response was seen as early as 2 weeks, with greatest control of disease at 6 months. 32 patients were on ciclosporin for a period of 1 year or longer, of whom only 1 had a greater than 30% increase in creatinine that crossed the upper limit of normal.

Conclusion: In our population, a lower dose likely resulted in a slower peak to greatest control, but was well tolerated with minimal renal impairment despite a relatively long average period of use.

Keywords: Asian; Ciclosporin; atopic dermatitis; cyclosporine A; psoriasis.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Asian People
  • Child
  • Cyclosporine / administration & dosage*
  • Cyclosporine / therapeutic use
  • Eczema / drug therapy*
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Cyclosporine